Floatz logo

Melphalan Flufenamide

Colorectal Neoplasms

PfizerSmall moleculePhase 3Dormant
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
35/ 100
Competitive Position
73/ 100

Competitive context

118 Active assets in the Colorectal Neoplasms cohort.

Asset / SponsorPhaseRating
Eloxatin
Peking University Cancer Hospital & Institute
Phase 4BBB
FLUOROURACILUM
Rutgers, The State University of New Jersey
Phase 4BBB
Capecitabine
Rutgers, The State University of New Jersey
Phase 4BBB
Ferric Carboxymaltose [Ferinject]
Nottingham University Hospitals NHS Trust
Phase 4BBB
Irinotecan
Shanghai Zhongshan Hospital
Phase 4BBB

View all 50 →

Same molecule, other indications

Melphalan Flufenamide is also rated in:

plasma cell myelomaDormant
CC
Indicative ·
47 / 100
View asset →
kidney failureDormant
CC
Indicative ·
44 / 100
View asset →
plasma cell myelomaDormant
D
Indicative ·
30 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →